News

Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD; BBSE: DRP) announces that it has retained the services of Renmark Financial Communications Inc. to handle its investor relations activities for investment brokers and advisors across the U.S. and Canada. Renmark Financial will proactively articulate Dragon’s corporate messages and growth potential to professional investment brokers and advisors […]

Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD) (“the Company”) announced today that the Company has sold its Development and Manufacturing Agreement with Polymun Scientific Immunbiologische Forschung GmBh (“Polymun”) to AS Biotech AG, a Swiss company, for US$1 million. Prior to the acquisition of Oriental Wave Holding Limited in early 2005, Dragon entered into a […]

Dragon Pharmaceuticals (OTCBB: DRUG) is pleased to announce that it’s Brazilian partner, Itaca Laboratorios Ltda., has placed an additional order for $1.8 million worth of Dragon’s EPO for delivery in 4Q 2001. This is in addition to a previous order for $1.4 million placed in January of this year, and brings Dragon Pharmaceuticals’ total orders […]

The Board of Directors of Dragon Pharmaceuticals Inc. (TSX: DDD; OTC BB: DRUG) today announced the appointment of Dr. Alexander E. Wick as President. Dr. Wick will continue to serve as a Director of Dragon, a position he has held since the Company’s inception in 1998. Dr. Longbin Liu, Dragon’s co-founding President and CEO, has […]

Dragon Pharmaceuticals Inc. (OTC BB: DRUG) is pleased to announce that it has entered into an agreement related to a novel, slow-release formulation for Erythropoietin (EPO) with Transworld Pharmaceuticals Corp. of Portugal and Renapharm AB of Sweden. EPO has been the most effective drug for the treatment of severe anemia since its introduction in 1989 […]

Dragon Pharmaceuticals Inc. (“Dragon”) is pleased to announce that it has acquired the rights and technology relating to the production of a Hepatitis B vaccine from Alphatech Bioengineering Limited, a Hong Kong corporation. The technology acquired from Alphatech involves the application of genetic techniques for the expression and purification of recombinant Hepatitis B vaccine protein […]

Dragon Pharmaceuticals Inc. announced today that it will proceed with a private placement of up to 4,000,000 units at US$2.00 per unit for total gross proceeds of up to US$8.0 million. Each unit consists of one Common Share in the Company and one Warrant to purchase an additional one-half Common Share at US$2.00 for a […]

Dragon Pharmaceuticals Inc. (OTCBB – DRUG.OB) is pleased to announce that it has entered into a marketing and licensing agreement with Standard Chemical & Pharmaceutical Co., Ltd. (“Standard”) of Taiwan for the distribution of Dragon’s recombinant Erythropoietin (EPO). EPO has been the most effective drug for the treatment of severe anemia since its introduction in […]

Dragon Pharmaceuticals Inc. is pleased to announce that it has entered into a marketing and licensing agreement with Jelfa S.A. of Poland for the distribution of Erythropoietin (EPO), a blood growth protein used to treat anemia, in Central and Eastern Europe and the Commonwealth of Independent States (“CIS”). The agreement grants Jelfa, the second largest […]

Dragon Pharmaceuticals Inc. is pleased to announce that it has been granted regulatory approval from the Chinese State Drug Administration (SDA) to enter Phase II clinical trials for two additional applications of the company’s lead product Erythropoietin (EPO). The efficacy of Dragon’s EPO, which stimulates the production of red blood cells, will be evaluated in […]